PUBLISHER: Grand View Research | PRODUCT CODE: 2188618
PUBLISHER: Grand View Research | PRODUCT CODE: 2188618
The global lipid nanoparticle formulation & development services market size was valued at USD 410.0 million in 2025 and is projected to grow from USD 447.8 million in 2026 to USD 918.8 million by 2033, at a CAGR of 10.8% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 43.6% in 2025. The market growth is driven by increasing demand for advanced drug delivery systems, growing adoption of mRNA-based therapeutics and vaccines, rising investments in nanomedicine, and expanding applications of lipid nanoparticles in gene therapy, oncology, and drug development.
Market Concentration & Characteristics
The degree of innovation in the lipid nanoparticle formulation & development services industry is high, driven by advances in artificial intelligence-assisted lipid discovery, high-throughput screening, microfluidic formulation, and targeted LNP design. For instance, in July 2024, researchers reported the AI-Guided Ionizable Lipid Engineering (AGILE) platform, which combines deep learning with combinatorial chemistry to accelerate the design and screening of ionizable lipids for mRNA delivery. The platform enables rapid identification of cell-specific lipid candidates, improving formulation development efficiency and supporting more targeted and effective LNP-based delivery.
The lipid nanoparticle formulation & development services industry is witnessing moderate M&A activity, as companies seek to expand specialized formulation and CDMO capabilities. For instance, in September 2024, Agilent Technologies completed its acquisition of BIOVECTRA for approximately USD 925 million, adding BIOVECTRA's lipid nanoparticle (LNP) formulation, pDNA, and mRNA capabilities to its CDMO portfolio. The acquisition strengthens Agilent's end-to-end biopharmaceutical development and manufacturing services and expands access to specialized LNP formulation capabilities.
"We are delighted to officially welcome the BIOVECTRA team to Agilent. This acquisition demonstrates our commitment to providing customers the most advanced capabilities to accelerate their therapeutics programs, including best-in-class cGMP pharmaceutical manufacturing."
Padraig McDonnell, Agilent President and CEO.
The impact of regulations on the lipid nanoparticle formulation and development services market is high, as regulatory requirements increasingly emphasize the characterization and control of critical quality attributes of LNP-based products. For instance, in March 2025, the European Medicines Agency (EMA) published a draft guideline on the quality of mRNA vaccines specifying quality considerations for LNPs, including lipid identity and content, particle size, polydispersity, mRNA encapsulation efficiency, and lipid-related impurities. These requirements increase demand for specialized LNP formulation, analytical characterization, process development, and quality-control services.
The lipid nanoparticle formulation and development services market is witnessing product expansion through the introduction of integrated LNP development and manufacturing services. For instance, in March 2025, Biomay announced GMP services for lipid-based nanoparticles, expanding its platform to include LNP formulation, process development, analytical assay development, characterization, release testing, and aseptic filling. The expanded offering provides an integrated pathway from mRNA production through LNP formulation and filling, supporting the development and manufacturing of RNA-based therapeutics.
The lipid nanoparticle formulation and development services market is witnessing regional expansion as specialized CDMOs increase LNP formulation and manufacturing capacity in key biopharmaceutical markets. For instance, in August 2026, Evonik announced a new GMP manufacturing facility in Vancouver, Canada, to expand its lipid-based drug delivery capabilities, including LNP development and clinical drug product manufacturing. The investment is expected to more than triple manufacturing capacity and strengthen Evonik's regional presence and global LNP formulation and manufacturing network, supporting growing demand for specialized development services.
"Lipid-based drug delivery technologies are already enabling the next generation of medicines. With the support of the Canadian federal government, this investment builds on our long-standing expertise in the field, enabling the development and commercialization of more life-changing therapies"
Lauren Kjeldsen, member of Evonik's Executive Board and COO for the Custom Solutions segment at Evonik.
Global Lipid Nanoparticle Formulation & Development Services Market Report Segmentation
This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global lipid nanoparticle formulation & development services market report based on service, payload type, scale of operation, end user, and region: